

# Roche - GSK - EMILIA: TDM1 ready to take over Tykerb

<https://marketpublishers.com/r/R745252F9EAEN.html>

Date: March 2012

Pages: 3

Price: US\$ 90.00 (Single User License)

ID: R745252F9EAEN

## Abstracts

Today, Roche and ImmunoGen announced the topline data from EMILIA study which met the primary end point of Progression free survival significantly. The study explored the use of Trastuzumab Emtansine (TDM1) against Tykerb and Xeloda in more than 950 patients with HER2 positive metastatic breast cancer whose disease progressed after initial treatment with Herceptin and a taxane based chemotherapy (second line setting). We forecast peak sales of \$500m for T-DMI in this indication and this should come at the expense of GSK's Tykerb, which is the current standard of care in this setting. This is the second study in Herceptin failure patients to demonstrate benefit. Earlier, T-DM1 in two PhII studies, VOGEL and KROP had demonstrated an impressive median PFS of 7.3 m and 4.9 m as a third line treatment option in patients who have failed Tykerb and/or Herceptin and /or chemotherapies.

## Contents

### COMPANIES MENTIONED

ROCHE, GLAXOSMITHKLINE

## I would like to order

Product name: Roche - GSK - EMILIA: TDM1 ready to take over Tykerb

Product link: <https://marketpublishers.com/r/R745252F9EAEN.html>

Price: US\$ 90.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/R745252F9EAEN.html>